Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesThe impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
International Journal of Cancer, 06/16/09
Zarogoulidis K et al. - In a study to examine the clinical impact of zoledronic acid (ZOL) with a focus on the survival, time to progression, and pain effect in lung cancer pts with bone metastases, it was concluded that the addition of ZOL increases overall survival in lung cancer pts with bone metastases. The longer the period of receiving ZOL, the better effect on survival and time to progression.
Methods- Lung cancer pts (n = 144, Stage IV) with evidence of metastasis bone scan were included.
- 87 of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 pts received no ZOL (Group B).
- All pts were treated with a combination chemotherapy that consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6.
- Group A had a statistically significant longer survival when compared to Group B.
- A statistically significant positive correlation was found between number of cycles of therapy with ZOL and total patient survival and time to progression.
- Pain effect of ZOL had no significant difference between the 2 groups of pts.
- Urine N-telopeptide of type I collagen (NTx) levels decreased in pts with NTx ≤29 nM BCE/mM creatinine at baseline after treatment with ZOL.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension
The Journal of Pediatrics, 10/19/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Annals of Internal Medicine, 10/20/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor